CanSino Biologics Inc. (HKG:6185)
46.26
+1.98 (4.47%)
Oct 31, 2025, 4:08 PM HKT
CanSino Biologics Revenue
CanSino Biologics had revenue of 310.24M CNY in the quarter ending September 30, 2025, with 17.67% growth. This brings the company's revenue in the last twelve months to 971.83M, up 29.83% year-over-year. In the year 2024, CanSino Biologics had annual revenue of 846.34M with 137.01% growth.
Revenue (ttm)
971.83M CNY
Revenue Growth
+29.83%
P/S Ratio
15.09
Revenue / Employee
879.48K CNY
Employees
1,105
Market Cap
16.03B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 846.34M | 489.25M | 137.01% |
| Dec 31, 2023 | 357.08M | -677.51M | -65.49% |
| Dec 31, 2022 | 1.03B | -3.27B | -75.94% |
| Dec 31, 2021 | 4.30B | 4.27B | 17,174.82% |
| Dec 31, 2020 | 24.89M | 9.28M | 59.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 35.81B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |
CanSino Biologics News
- 6 months ago - CanSino Biologics CEO on earnings, business outlook, and international partnerships - CNBC
- 3 years ago - Riding Covid Vaccine Highs, CanSino Plans Swiss Listing - Seeking Alpha
- 3 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 3 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 3 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 3 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 3 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 3 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire